Other BH3-mimetics selectively targeting other pro-survival proteins include A1331852, which inhibits BCL-XL and the recently described MCL1 inhibitor S63845, which our group has shown to be well tolerated in mice and active against a number of malignancies, including a subset of AML at low nanomolar concentrations [8, 9]. This evidence concerns the gene BCL2L1 and acute myeloid leukemia.